Investors

Press Releases

Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Endonovo Therapeutics (ENDV): Targeting $20+ Billion Market for In Vitro ADME and Toxicology Testing
Endonovo Therapeutics Announces Registration Statement on Form S-1 has been Declared Effective
Endonovo Therapeutics Issues Corporate Update
Endonovo Therapeutics Receives Notice of Termination of Its Binding-Letter Agreement to Acquire Rio Grande Neurosciences
Endonovo Therapeutics Files Patent for Treating Chemical and Radiation Injuries Using Next-Generation Biologics
Endonovo Therapeutics Announces Issuance of U.S. Patent on Production of Human Biomolecules
Endonovo Therapeutics Announces New Round of Financing
Endonovo Therapeutics Announces Binding Letter of Intent to Acquire Rio Grande Neurosciences, Inc.
RSS
Show All